Physician profile
Jane E Kienle
NPI 1740398676
$2,961.94
in general payments reported to CMS, 2019-2025
18 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,581 · 2020: $99.38 · 2022: $56.37 · 2023: $152 · 2024: $791 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $633.89 | 2019-2025 | Repatha, Otezla, Evenity |
| Regeneron Healthcare Solutions, INC. | $544.44 | 2019-2024 | Evkeeza |
| Novartis Pharmaceuticals Corporation | $362.44 | 2022-2025 | |
| Amarin Pharma, INC. | $352.02 | 2019 | |
| Lilly USA, LLC | $240.79 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $196.71 | 2024-2025 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $120.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $106.86 | 2019 | |
| Eisai INC. | $93.02 | 2024-2025 | |
| Regeneron Pharmaceuticals, INC. | $74.86 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.63 | 2024 | |
| Glaxosmithkline, LLC. | $42.99 | 2024 | Trelegy Ellipta |
| Abbvie INC. | $33.04 | 2023-2024 | |
| Esperion Therapeutics, INC. | $30.19 | 2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $30.09 | 2022-2024 | Livalo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $24.09 | 2023 | |
| Pfizer INC. | $18.62 | 2025 | |
| Amryt Pharma Holdings Ltd | $13.43 | 2023 | Juxtapid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Kienle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.